-
11.发明申请公开(公告)号：US20180177750A1
公开(公告)日：2018-06-28
申请号：US15851053
申请日：2017-12-21
Applicant: Arvinas, Inc.
Inventor： Andrew P. Crew , Lawrence B. Snyder , Jing Wang , Hanqing Dong , Yimin Qian , Michael Berlin
IPC: A61K31/166 , A61K31/405 , A61K47/54 , A61K31/351 , A61K38/45 , C12N9/10 , A61P35/00
CPC classification number: A61K31/166 , A61K31/351 , A61K31/405 , A61K38/45 , A61K47/545 , A61K47/55 , A61K47/555 , A61P35/00 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C12N9/1007 , C12Y201/01043
Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号：US20160376598A1
公开(公告)日：2016-12-29
申请号：US15171883
申请日：2016-06-02
Applicant: The General Hospital Corporation
Inventor： Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
IPC: C12N15/113 , C12Q1/68
CPC classification number: C12N15/1137 , A61K9/1271 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/314 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/346 , C12N2320/30 , C12N2320/32 , C12N2330/31 , C12Q1/6876 , C12Q1/6881 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , C12Y201/01043
Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸和用于靶向lncRNA的方法和组合物。
-
公开(公告)号：US20160355813A1
公开(公告)日：2016-12-08
申请号：US15171706
申请日：2016-06-02
Applicant: The General Hospital Corporation
Inventor： Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
IPC: C12N15/113
CPC classification number: C12N15/1137 , A61K9/1271 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/314 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/346 , C12N2320/30 , C12N2320/32 , C12N2330/31 , C12Q1/6876 , C12Q1/6881 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , C12Y201/01043
Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
-
公开(公告)号：US09328346B2
公开(公告)日：2016-05-03
申请号：US13884670
申请日：2011-11-12
Applicant: Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
Inventor： Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
IPC: C12N15/11 , C12N15/113
CPC classification number: C12N15/1137 , A61K9/1271 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/314 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/346 , C12N2320/30 , C12N2320/32 , C12N2330/31 , C12Q1/6876 , C12Q1/6881 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , C12Y201/01043
Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸以及用于靶向lncRNA的方法和组合物。
-
公开(公告)号：US20150297611A1
公开(公告)日：2015-10-22
申请号：US14440567
申请日：2013-11-04
Applicant: DUKE UNIVERSITY
Inventor： Victor J. Dzau , Maria Mirotsou
IPC: A61K31/551 , C07D401/14 , C07D487/04 , A61K31/437 , A61K45/06
CPC classification number: A61K31/551 , A61K31/437 , A61K35/34 , A61K45/06 , A61P9/00 , A61P9/10 , A61P9/12 , C07D401/14 , C07D487/04 , C12N15/1137 , C12N2310/141 , C12N2320/30 , C12Y201/01043 , C12Y201/01125 , C12Y207/10002 , C12Y207/11001
Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.
Abstract translation: 通过使非心肌细胞或组织与组蛋白甲基转移酶活性或表达的调节剂接触来促进非心肌细胞或组织的重编程的方法，所述心肌细胞或组织被重组为心肌细胞或组织。
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20150212088A1
公开(公告)日：2015-07-30
申请号：US14605519
申请日：2015-01-26
Applicant: The Regents of the University of Michigan
Inventor： Weiping Zou , Ilona Kryczek
IPC: G01N33/574 , C07K16/28 , C12Q1/68 , A61K45/06 , A61K39/395 , C12N15/113 , C07K16/24 , A61K31/7076
CPC classification number: G01N33/57419 , A61K31/7076 , A61K31/7105 , A61K31/713 , A61K45/06 , C07K16/244 , C07K2317/76 , C12N15/1136 , C12N15/1137 , C12N2310/14 , C12N2310/531 , C12Q1/6886 , C12Q2600/158 , C12Y201/01043 , G01N2333/4706 , G01N2333/54 , G01N2333/91017 , A61K2300/00
Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.
Abstract translation: 本发明涉及用于检测，治疗和经验性研究受试者的免疫系统和癌症干细胞之间相互作用的组合物和方法。 特别地，本发明提供了在癌症的诊断，治疗和实证研究中使用IL-22细胞因子信号传导和/或下游靶IL-22细胞因子信号传导的组合物和方法（例如，STAT3，DOT1L，SUZ12，EED） 其特征在于通过IL-22细胞因子信号传导而激活的癌症干细胞。
-
公开(公告)号：US20140142160A1
公开(公告)日：2014-05-22
申请号：US13884670
申请日：2011-11-12
Applicant: Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
Inventor： Jeannie T. Lee , Jing Zhao , Kavitha Sarma , Mark Borowsky , Toshiro Kendrick Ohsumi
IPC: C12N15/113
CPC classification number: C12N15/1137 , A61K9/1271 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/314 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/346 , C12N2320/30 , C12N2320/32 , C12N2330/31 , C12Q1/6876 , C12Q1/6881 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , C12Y201/01043
Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸以及用于靶向lncRNA的方法和组合物。
-
公开(公告)号：US20110064664A1
公开(公告)日：2011-03-17
申请号：US12680728
申请日：2008-10-08
Applicant: Gabriel Lopez-Berestein , Eylem Ozturk , Angela Sanguino , Anil Sood , Emir Baki Denkbas
Inventor： Gabriel Lopez-Berestein , Eylem Ozturk , Angela Sanguino , Anil Sood , Emir Baki Denkbas
IPC: A61K49/00 , A61K47/30 , A61K38/02 , A61K39/395 , A61K31/7052 , C12Q1/68 , C40B30/00 , A61P35/00
CPC classification number: A61K31/722 , A61K9/5115 , A61K9/5161 , A61K9/5192 , A61K31/575 , A61K31/713 , A61K45/06 , A61K47/02 , A61K47/36 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12Y201/01043
Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent is about 15.0 or less. Also disclosed are nanoparticles that include a chitosan and an inhibitor of enhancer of Zeste homologue 2 (EZH2). Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease and methods of predicting prognosis of ovarian cancer in a subject that involve determining the expression and/or function of EZH2 in the subject are also disclosed.
Abstract translation: 公开了用于将治疗剂或诊断剂递送至包含壳聚糖和多磷酸盐的受试者的纳米颗粒，其中壳聚糖与多磷酸盐的重量比为约1.0或更大，并且多磷酸盐与治疗剂的重量比 药剂或诊断剂的含量约为15.0或更低。 还公开了包含壳聚糖和Zeste同系物2（EZH2）增强子抑制剂的纳米颗粒。 还公开了将治疗剂或诊断剂递送到受试者以治疗或预防疾病的方法以及预测受试者中涉及确定受试者中EZH2的表达和/或功能的卵巢癌预后的方法。
-
公开(公告)号：US12024715B2
公开(公告)日：2024-07-02
申请号：US16761599
申请日：2018-11-07
CPC classification number: C12N5/0636 , A61K35/17 , A61P35/00 , C07K16/2803 , C12N9/1007 , C12N15/85 , C12Y201/01043 , C07K2317/24 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2510/00
Abstract: The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.
-
公开(公告)号：US20230399640A1
公开(公告)日：2023-12-14
申请号：US18246480
申请日：2021-09-24
Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.
Inventor： Jodi Michelle KENNEDY , Jeremiah Dale FARELLI
IPC: C12N15/11 , C12N9/22 , C12N9/10 , C07K14/195
CPC classification number: C12N15/11 , C12N9/22 , C12N9/1007 , C12Y201/01043 , C07K14/195 , C12N2310/20 , C07K2319/80
Abstract: The present disclosure relates to expression repressors and expression repression systems for modulating expression of a target gene in a cell.
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.068 seconds)
